Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Intelligence

Set Alert for Market Intelligence

Newron Needs To Up Ante In Large-Scale Schizophrenia Studies

Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.

Clinical Trials Neurology Research and Development Strategies
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

Commercial Market Intelligence

Microbiome Market Value To Reach $500m by 2022

The microbiome market will see its value rise to $500m by 2022, and higher during the next decade. The key driver will be the increase in biotech and pharma firms looking at the emerging research space for new therapeutic options to treat chronic conditions such as Crohn’s disease.

Research & Development Research and Development Strategies

New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack

Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.

Clinical Trials Market Intelligence

Pharma's Orphan Drug Activity, An Infographic – Corrected Version

More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases. Effective orphan drug legislation and incentivization programs introduced gradually around the world since the 1980s mean rare diseases are no longer a rare sighting in the pharma industry pipeline, as this infographic illustrates.

Market Intelligence Rare Diseases

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV

While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.

Business Strategies Commercial

AZ’s ZS-9 Targets Hyperkalemia Sector As It Nears EU Market

A potential near-blockbuster drug, AstraZeneca’s Lokelma (ZS-9), has received a positive opinion from Europe’s CHMP and, if approved, will soon have to justify best-in-class plaudits and a hefty acquisition price.

Approvals Market Intelligence
See All
UsernamePublicRestriction

Register